Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas



Status:Recruiting
Conditions:Cancer, Lymphoma
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:1/16/2019
Start Date:July 2015
End Date:October 2021
Contact:Laksmi Wilson
Email:Laksmi.Wilson@astx.com
Phone:+1-925-560-2914

Use our guide to learn which trials are right for you!

Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas

This is an open-label, dose-escalation Phase 1/2 study to assess the safety of ASTX660,
determine the maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D), and recommended
dosing regimen, and to obtain preliminary efficacy, pharmacokinetic (PK), and target
engagement data, in subjects with advanced solid tumors or lymphoma for whom standard
life-prolonging measures are not available.

ASTX660 is a synthetic small molecule dual antagonist of cellular inhibitor of apoptosis
protein (cIAP) 1 and X-linked inhibitor of apoptosis protein (XIAP) that has been shown to
have potent proapoptotic and tumor growth inhibitory activity in nonclinical models. ASTX660
has not been previously evaluated in human subjects. The Phase 1 portion of the study will
determine the MTD, RP2D, and recommended dosing regimen. The Phase 2 portion will evaluate
activity in selected tumor types.

Subjects will continue to receive their assigned treatment throughout the study until the
occurrence of disease progression, death, or unacceptable treatment-related toxicity, or
until the study is closed by the sponsor.

Tolerability and safety of study treatment will be evaluated throughout the study by
collection of clinical and laboratory data. In Phase 2, antitumor response will be assessed
using computed tomography (CT) or magnetic resonance imaging (MRI) scans or other appropriate
disease evaluation methods. In subjects with solid tumors, response will be evaluated
according to standard Response Evaluation Criteria in Solid Tumors (RECIST v1.1; Appendix 3).
In subjects with DLBCL and PTCL, antitumor response will be evaluated according to the 2014
Lugano classification (Appendix 5). In subjects with CTCL, global overall response criteria
will be used, based on skin, blood, node, and viscera assessments (Appendix 4).

Inclusion Criteria:

1. Able to understand and comply with the protocol and study procedures, understand the
risks involved in the study, and provide written informed consent before any
study-specific procedure is performed.

2. Men and women 18 years of age or older.

3. Subjects with histologically or cytologically confirmed advanced solid tumors or
lymphoma that is metastatic or unresectable, and for whom standard life-prolonging
measures are not available. Specific tumor types that will be selected for study in
Phase 2 are detailed in the protocol.

4. In the Phase 2 portion of the protocol only, subjects must have measurable disease
according to response criteria appropriate for their type of cancer (as explained in
Section 9.1).

5. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.

6. Acceptable organ function, as evidenced by the following laboratory data:

1. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <=2.0 * upper
limit of normal (ULN).

2. Total serum bilirubin <=1.5 * ULN

3. Absolute neutrophil count (ANC):

- Phase 1 and 2 (except Phase 2 subjects with known lymphoma) >=1500 cells/mm3

- Phase 2 subjects with known lymphoma: >=1000 cells/mm3 (>750 cell/mm3 for
subjects with lymphoma in bone marrow)

4. Platelet count:

- Phase 1 and 2 (except Phase 2 subject with known lymphoma) >=100,000
cells/mm3

- Phase 2 subjects with known lymphoma: >= 50,000 cells/mm3; >=25,000
cells/mm3 for subjects with lymphoma in bone marrow

5. Serum creatinine levels <= 1.5 * ULN, or calculated (by Cockcroft-Gault formula
or other accepted formula) or measure creatinine clearance >=50 mL/min.

6. Amylase and lipase <=ULN [Applies to Phase 2].

7. Women of child-bearing potential (according to recommendations of the Clinical Trial
Facilitation Group [CTFG]; see protocol for details) must not be pregnant or
breastfeeding and must have a negative pregnancy test at screening. Women of
child-bearing potential and men with female partners of child-bearing potential must
agree to practice 2 highly effective contraceptive measures of birth control (as
described in the protocol) and must agree not to become pregnant or father a child
while receiving treatment with study drug and for at least 3 months after completing
treatment. Contraceptive measures which may be considered highly effective comprise
combined hormonal contraception (oral, vaginal, or transdermal) or progestogen-only
hormonal contraception (oral, injectable, implantable) associated with inhibition of
ovulation, intrauterine device, intrauterine hormone-releasing system, bilateral tubal
occlusion, sexual abstinence, and surgically successful vasectomy. Abstinence is
acceptable only if it is consistent with the preferred and usual lifestyle of the
subject. Periodic abstinence (eg, calendar, ovulation, symptothermal, or postovulation
methods) and withdrawal are not acceptable methods of birth control.

Exclusion Criteria:

1. Hypersensitivity to ASTX660, excipients of the drug product, or other components of
the study treatment regimen.

2. Poor medical risk because of systemic diseases (e.g. active uncontrolled infections)
in addition to the qualifying disease under study.

3. Life-threatening illness, significant organ system dysfunction, or other condition
that, in the investigator's opinion, could compromise subject safety or the integrity
of the study outcomes, or interfere with the absorption or metabolism of ASTX660.

4. History of, or at risk for, cardiac disease, as evidenced by 1 or more of the
following conditions:

1. Abnormal left ventricular ejection fraction (LVEF; <50%) or echocardiogram ECHO
or multiple gated acquisition scan (MUGA). [Applies to Phase 1 only; ECHO/MUGA
scans are not performed in Phase 2.]

2. Congestive cardiac failure of >= Grade 3 severity according to New York Heart
Association (NYHA) functional classification defined as subjects with marked
limitation of activity and who are comfortable only at rest.

3. Unstable cardiac disease including angina or hypertension as defined by the need
for overnight hospital admission within the last 3 months (90 days).

4. History or presence of complete left bundle branch block, heart block, cardiac
pacemaker or significant arrhythmia.

5. Concurrent treatment with any medical that prolongs QT interval and may induce
torsades de pointes, and which cannot be discontinued at least 2 weeks before
treatment with ASTX660. [Applies to Phase 1 only].

6. Personal history of long QTc syndrome or ventricular arrhythmias including
ventricular bigeminy.

7. Screening 12-lead ECG with measurable QTc interval (according to either
Fridericia's or Bazett's correction) of >=470 msec).

5. Known history of human immunodeficiency virus (HIV) infection, or seropositive results
consistent with active hepatitis B virus (HBV) or active hepatitis C virus (HCV)
infection.

6. Grade 2 or greater neuropathy [Applies to Phase 1]. Grade 3 or greater neuropathy
[Applies to Phase 2].

7. Known brain metastases, unless stable or previously treated.

8. Known significant mental illness or other conditions such as active alcohol or other
substance abuse that, in the opinion of the investigator, predisposes the subject to
high risk of noncompliance with the protocol treatment or assessments.

9. Prior anticancer treatments or therapies within the indicated time window prior to
first dose of study treatment (ASTX660), as follows:

- Cytotoxic chemotherapy or radiotherapy within 3 weeks prior and any encountered
treatment-related toxicities (excepting alopecia) not resolved to Grade 1 or less
[Phase 1] or Grade 2 or less [Phase 2].

- Monoclonal antibodies within 4 weeks prior and any encountered treatment-related
toxicities not resolved to Grade 1 or less [Phase 1] or Grade 2 or less [Phase
2].

- Investigational drugs (small molecules or biologics) within the longer of 2 weeks
or 5 half-lives prior to study treatment and any encountered treatment-related
toxicities not resolved to Grade 1 or less [Phase 1] or Grade 2 or less [Phase
2].
We found this trial at
19
sites
4800 Friendship Avenue
Pittsburgh, Pennsylvania 15206
Phone: 412-578-1605
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
1720 2nd Ave S
Birmingham, Alabama 35233
(205) 934-4011 
Phone: 205-934-3061
University of Alabama at Birmingham The University of Alabama at Birmingham (UAB) traces its roots...
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
666 Elm Street
Buffalo, New York 14263
(716) 845-2300
Phone: 716-845-1359
Roswell Park Cancer Institute Welcome to Roswell Park Cancer Institute (RPCI), America's first cancer center...
?
mi
from
Buffalo, NY
Click here to add this to my saved trials
675 N Saint Clair St # 21-100
Chicago, Illinois 60611
(312) 695-1156
Phone: 312-695-0990
Robert H. Lurie Comprehensive Cancer Center at Northwestern University The cancer center was first established...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
8700 Beverly Blvd # 8211
Los Angeles, California 90048
(1-800-233-2771)
Phone: 310-248-6729
Cedars Sinai Med Ctr Cedars-Sinai is known for providing the highest quality patient care. Our...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Oklahoma City, Oklahoma 73104
Phone: 405-271-8001
?
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Atlanta, Georgia 30322
Phone: 404-778-5871
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Baltimore, Maryland 21231
Phone: 410-955-8839
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
617-632-3000
Phone: 617-632-3090
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
?
mi
from
Boston, MA
Click here to add this to my saved trials
Calgary, Alberta
Phone: 403-283-1651
?
mi
from
Calgary,
Click here to add this to my saved trials
Detroit, Michigan 48202
Phone: 313-916-9354
?
mi
from
Detroit, MI
Click here to add this to my saved trials
Houston, Texas 77030
Phone: 713-563-3559
?
mi
from
Houston, TX
Click here to add this to my saved trials
Los Angeles, California 90033
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
35 Park Street
New Haven, Connecticut 06510
?
mi
from
New Haven, CT
Click here to add this to my saved trials
New York, New York 10032
Phone: 212-326-5720
?
mi
from
New York, NY
Click here to add this to my saved trials
Richmond, Virginia 23298
Phone: 804-828-5057
?
mi
from
Richmond, VA
Click here to add this to my saved trials
Scottsdale, Arizona 85258
Phone: 480-860-5000
?
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Seattle, Washington 98109
Phone: 206-288-6739
?
mi
from
Seattle, WA
Click here to add this to my saved trials
Winston-Salem, North Carolina 27157
Phone: 336-716-8664
?
mi
from
Winston-Salem, NC
Click here to add this to my saved trials